徐晓明,尹春梅,严志凌,胡艳,杨宏英
XU Xiaoming,YIN Chunmei,YAN Zhiling,HU Yan,YANG Hongying

• 1:昆明医科大学第三附属医院

摘要(Abstract)：

目的:探讨Toll样受体9(TLR9)基因中的单核苷酸多态性(SNP)位点rs352139 C>T、rs352140 C>T和rs5743836 A>G与云南汉族人群宫颈癌发生发展的相关性。方法:选取云南地区汉族女性人群中宫颈癌患者253例、宫颈癌癌前病变患者92例,正常健康女性体检者330例,采用Taq Man探针基因分型的方法对TLR9基因的SNP位点进行基因分型,评估rs352139(C>T)、rs352140(C>T)和rs5743836(A>G)位点的等位基因、基因型以及构建的单倍型与宫颈癌发生发展的相关性。结果:TLR9基因SNP位点rs352139(C>T)、rs352140(C>T)、rs5743836(A>G)的基因型和等位基因在各组间的分布频率差异均无统计学意义(P>0.05),根据连锁不平衡结果构建的rs352139(C>T)、rs352140(C>T)和rs5743836(A>G)的单倍型在宫颈癌组和对照组中的分布频率差异无统计学意义(P>0.05)。结论:在云南汉族女性群体中,TLR9基因的3个SNP位点rs352139(C>T)、rs352140(C>T)和rs5743836(A>G)与宫颈癌的发生发展无相关性。
Objective: To explore the correlation of single nucleotide polymorphisms( SNPs)( rs352139 C > T、rs352140 C > T and rs5743836 A > G) in TLR9 gene with the occurrence and development of cervical cancer in Han population of Yunnan province. Method: Two hundred and fiftythree patients with cervical cancer( cancer group), 92 patients with precancerous lesion( PCL group),and 330 health individuals( control group) were recruited in this study,and the SNPs were genotyped by Taq Man Assay. The allelic genes,genotypes,and constructed haplotypes of loci of rs352139( C > T),rs352140( C > T),and s5743836( A > G) were analyzed,and correlation of them with the occurrence and development of cervical cancer was evaluated. Results: The allelic and genotypic frequencies of these three SNPs showed no significant difference among cancer,PCL,and control groups( P > 0. 05). The frequencies of haplotypes constructed by rs352139( C > T),rs352140( C >T) and rs5743836( A > G) also showed no significant difference between cancer and control groups(P > 0. 05). Conclusion: These three SNPs in TLR9 gene may not be associated with the occurrence and development of cervical cancer in the Han population of Yunnan province.

关键词(KeyWords)： Toll样受体9;多态性,单核苷酸;宫颈肿瘤;癌;云南;汉族
Toll-like receptor 9;polymorphisms,single nucleotide;cervical tumour;cancer;Yunnan;Han nationality

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目(81573206);; 云南省科技厅-昆明医科大学应用基础研究联合专项(201501UH01630);; 云南省卫生厅科技处资助项目(2014NS033)

作者(Author): 徐晓明,尹春梅,严志凌,胡艳,杨宏英
XU Xiaoming,YIN Chunmei,YAN Zhiling,HU Yan,YANG Hongying

DOI: 10.19367/j.cnki.1000-2707.2017.01.005

参考文献(References)：

• [1]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA:A Cancer Journal for Clinicians,2015(2):87-108.
• [2]Zidi S,Sghaier I,Gazouani E,et al.Evaluation of Tolllike receptors 2/3/4/9 gene polymorphisms in cervical cancer evolution[J].Pathology&Oncology Research,2016(2):323-330.
• [3]Kanzler H,Barrat FJ,Hessel EM,et al.Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists[J].Nature Medicine,2007(5):552-559.
• [4]Mukherjee S,Siddiqui MA,Dayal S,et al.Epigallocatechin-3-gallate suppresses proinflammatory cytokines and chemokines induced by Toll-like receptor 9 agonists in prostate cancer cells[J].J Inflamm Res,2014(7):89-101.
• [5]Wan GX,Cao YW,Li WQ,et al.Associations between TLR9 polymorphisms and cancer risk:evidence from an updated meta-analysis of 25 685 subjects[J].Asian Pac J Cancer Prev,2014(19):8279-8285.
• [6]Zhang L,Qin H,Guan X,et al.The TLR9 gene polymorphisms and the risk of cancer:evidence from a meta-analysis[J].PLo S One,2013(8):71785.
• [7]Li Z,Zhang Z,He Z,et al.A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers:update of the SHEsis[J].Cell Res,2009(4):519-523.
• [8]Shi YY,He L.SHEsis,a powerful software platform for analyses of linkage disequilibrium,haplotype construction,and genetic association at polymorphism loci[J].Cell Res,2005(2):97-98.
• [9]Cannella F,Pierangeli A,Scagnolari C,et al.TLR9 is expressed in human papillomavirus-positive cervical cells and is overexpressed in persistent infections[J].Immunobiology,2015(3):363-368.
• [10]Lee JW,Choi JJ,Seo ES,et al.Increased toll-like receptor 9 expression in cervical neoplasia[J].Mol Carcinog,2007(11):941-947.
• [11]Lange NE,Zhou X,Lasky-Su J,et al.Comprehensive genetic assessment of a functional TLR9 promoter polymorphism:no replicable association with asthma or asthma-related phenotypes[J].BMC Med Genet,2011(12):26-30.
• [12]Kikuchi K,Lian ZX,Kimura Y,et al.Genetic polymorphisms of toll-like receptor 9 influence the immune response to Cp G and contribute to hyper-Ig M in primary biliary cirrhosis[J].J Autoimmun,2005(4):347-352.
• [13]Lai ZZ,Zhang N,Pan XL,et al.Toll-like receptor 9(TLR9)gene polymorphisms associated with increased susceptibility of human papillomavirus-16 infection in patients with cervical cancer[J].J Int Med Res,2013(4):1027-1036.
• [14]Roszak A,Lianeri M,Sowinska A,et al.Involvement of Toll-like Receptor 9 polymorphism in cervical cancer development[J].Mol Biol Rep,2012(8):8425-8430.
• [15]Mu X,Zhao J,Yuan X,et al.Gene Polymorphisms of Toll-Like Receptor 9-1486 T/C and 2848 G/A in Cervical Cancer Risk[J].Int J Gynecol Cancer,2015(7):1173-1178.
• [16]Shahin RM,El KE,Khalifa RH,et al.Contribution of Toll-Like Receptor 9 Gene Single-Nucleotide Polymorphism to Systemic Lupus Erythematosus in Egyptian Patients[J].Immunol Invest,2016(3):235-242.

文章评论(Comment)：